Author(s): Calabr L, Maio M, Calabr L, Maio M
Abstract Share this page
Abstract Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with refractory malignant mesothelioma, a deadly disease with no effective therapeutic options.
This article was published in Oncoimmunology
and referenced in Journal of Cancer Science & Therapy